The Centers for Medicare & Medicaid Services released final negotiated prices from the Inflation Reduction Act’s second bargaining round, listing 15 drugs including semaglutide products used for diabetes and obesity. CMS estimated that if the 2027 prices had been in effect in 2024 they would have cut aggregate net drug spending by roughly 44% (36% accounting for other Part D changes), with $685 million lower out‑of‑pocket costs for beneficiaries. The list includes high‑expenditure oncology, respiratory and metabolic drugs; CMS said some prices were set after revised counteroffers while others reflect accepted final offers. Implementation timelines and legal challenges remain uncertain as affected manufacturers and stakeholders weigh appeals and reimbursement adjustments.